Press

Information for our users and the media.
For press inquiries, please contact Simon Smith at simon@benchsci.com.

Our Story

Backed by Google’s AI fund, Gradient Ventures, BenchSci spent 3 years teaching a computer to read biomedical papers like a PhD scientist.

Today, BenchSci is the world's most comprehensive AI-driven biomedical discovery platform. Powered by state-of-the-art machine learning, our AI has read millions of scientific documents. This includes  more than 9 million biomedical papers and more than 5.8 million compound specifications.

Using BenchSci, scientists now have the world's biomedical knowledge at their fingertips. In an instant, they can get novel scientific insights, including for materials and methods. These are insights they can trust, derived from millions of successful experiments. This catalyzes their research and increases the velocity of discovery.

BenchSci was born in the birthplace of modern machine learning, Toronto. Its creators are biomedical scientists, computational biologists, and machine learning engineers. They experienced first-hand the expensive inefficiency of data gaps and literature searches. Together, they developed technology to overcome them. This technology uses machine learning to read scientific documents and distill their knowledge. This knowledge is then stored in a graph of relationships. Researchers can query the graph to ask complex questions and receive evidence-based answers.

Just over a year from launch, BenchSci was already powering research in 15 of the top 20 pharmaceutical companies and more than 2,000 academic institutions. Our first application is resolving the antibody crisis. Leveraging our comprehensive biological knowledge graph, BenchSci guides research antibody selection. Researchers can find antibodies by target, technique, and 15 experimental variables.

We're now expanding the questions our knowledge graph can answer. In 2019, our AI will unlock insights into siRNAs, plasmids, and recombinant proteins. Our platform will also scale to encompass more compounds, cell lines, and tissues. And it will branch out to new data sources, including patents.

This evolution will allow us to address broader discovery challenges. These include patient cohort identification and patent decoding. BenchSci will also be capable of guiding experimental design by understanding knowledge about disease pathways, proteins, and genes currently encoded in the world's published scientific literature.

FAST FACTS
Founded in
2015 by Tom Leung, David Q. Chen, Elvis Wianda, and Liran Belenzon
Headquarters
Toronto, Canada
Employees
40
Official launch
July 2017
Papers analyzed
9,409,849
Antibody products analyzed
5,832,469
Antibody use cases identified
4,700,762
Press Articles
Biotech Chief Data Officer Milind Kamkolkar Joins Advisory Board of AI-Powered Life Science R&D Accelerator BenchSci
BenchSci Press Release
Biotech Chief Data Officer Milind Kamkolkar Joins Advisory Board of AI-Powered Life Science R&D Accelerator BenchSci
Appointment reinforces Google AI fund-backed company's leadership in using machine learning to drive faster, more cost-effective, and higher impact biomedical discoveries.
READ ARTICLE
Active Motif Partners with BenchSci to Increase Discoverability of Epigenetics-related Products
Active Motif
Active Motif Partners with BenchSci to Increase Discoverability of Epigenetics-related Products
Partnership will leverage BenchSci’s artificial intelligence to help researchers find the right antibodies faster than ever before.
READ ARTICLE
Gradient Ventures Founding Partner Ankit Jain Joins Board of Biomedical AI Startup BenchSci
BenchSci Press Release
Gradient Ventures Founding Partner Ankit Jain Joins Board of Biomedical AI Startup BenchSci
Appointment made as BenchSci announces a more than 5x increase in biomedical experiments understood by its machine learning technology.
READ ARTICLE
Proteintech Partners With BenchSci to Boost Researchers' Antibody Data Searches
Proteintech
Proteintech Partners With BenchSci to Boost Researchers' Antibody Data Searches
Partnership will accelerate science with "rocket fuel" that lets researchers make better decisions faster than ever before.
READ ARTICLE
GeneTex Partners With BenchSci to Augment Antibody Catalog Publication Data
GeneTex
GeneTex Partners With BenchSci to Augment Antibody Catalog Publication Data
Partnership will use BenchSci's artificial intelligence to help researchers run successful experiments with the right antibody.
READ ARTICLE
Bio-Techne Partners with BenchSci to Enhance Available Publication Data of Its Commercial Antibodies
Bio-Techne
Bio-Techne Partners with BenchSci to Enhance Available Publication Data of Its Commercial Antibodies
Novus Biologicals and R&D Systems will list their catalog of antibodies on BenchSci to increase the amount of published antibody validation data available to researchers.
READ ARTICLE
Accomplished Life Science Entrepreneur Karen Padgett Joins BenchSci Advisory Board
BenchSci Press Release
Accomplished Life Science Entrepreneur Karen Padgett Joins BenchSci Advisory Board
Founder of Novus Biologicals will guide use of AI to empower antibody suppliers.
READ ARTICLE
Thermo Fisher Scientific to Provide Antibody Publication Data on its Website
Thermo Fisher Scientific
Thermo Fisher Scientific to Provide Antibody Publication Data on its Website
Researchers can view published data on antibodies directly on the website to help better understand antibody performance.
READ ARTICLE
BenchSci Ranked One of the Top 25 Up and Coming Technology Companies on the Branham300
BenchSci Press Release
BenchSci Ranked One of the Top 25 Up and Coming Technology Companies on the Branham300
Recognition follows news of BenchSci becoming the first non-US company to receive investment from Gradient Ventures, Google’s AI-focused venture fund.
READ ARTICLE
Lab Launch Inc. Partners with BenchSci to Provide Startups Time-Saving Research Tools
BenchSci Press Release
Lab Launch Inc. Partners with BenchSci to Provide Startups Time-Saving Research Tools
BenchSci, an AI-driven platform that decodes published figures to help scientists find antibody usage data, is partnering with Lab Launch Inc., a nonprofit biotechnology incubator supporting startups in the Los Angeles area.
READ ARTICLE
The Path to VICTORy – a Beginner's Guide to Success Using Commercial Research Antibodies
The Company of Biologists
The Path to VICTORy – a Beginner's Guide to Success Using Commercial Research Antibodies
Author Simon L. Goodman cites BenchSci as a tool that can help address issues with antibodies that contribute to the reproducibility crisis.
READ ARTICLE
Karger Publishers Partners with BenchSci to Help Scientists Find the Right Products for Their Experiments
Karger
Karger Publishers Partners with BenchSci to Help Scientists Find the Right Products for Their Experiments
READ ARTICLE
Canada's BenchSci Gets Cash Infusion from Google Parent Alphabet
CBC
Canada's BenchSci Gets Cash Infusion from Google Parent Alphabet
"Tom Leung, co-founder and chief scientist of BenchSci, talks about Google’s parent, Alphabet, investing millions in the Toronto biomedical startup, which uses AI to help scientists sift through research papers for scientific discoveries and product reviews."
READ ARTICLE
Alphabet's AI Venture Capital Firm Makes First Investment in Canada with BenchSci
The Globe and Mail
Alphabet's AI Venture Capital Firm Makes First Investment in Canada with BenchSci
"Alphabet Inc.’s nascent artificial-intelligence venture fund has picked its first Canadian investment: BenchSci, a Toronto biomedical startup that uses machine learning to scan millions of data points in biomedical research papers, generating searchable results to help shorten the drug discovery process."
READ ARTICLE
BenchSci Raises US$8 Million Series A to Accelerate Biomedical Discoveries with AI-Powered Search Engine for Biological Products
BenchSci Press Release
BenchSci Raises US$8 Million Series A to Accelerate Biomedical Discoveries with AI-Powered Search Engine for Biological Products
Latest round of funding from iNovia Capital, Gradient Ventures, and others positions BenchSci to execute on its mission, and take its place in the market as one of the world’s top machine learning companies.
READ ARTICLE
Responsible Science
Science: Disrupt
Responsible Science
BenchSci CSO Tom Leung contributes to a discussion on startups making science more responsible through new technologies and tools.
READ ARTICLE
Wiley Partners with BenchSci to Give Scientists Unprecedented Insight into Biological Products
BenchSci Press Release
Wiley Partners with BenchSci to Give Scientists Unprecedented Insight into Biological Products
John Wiley and Sons Inc. today announced that it has partnered with BenchSci, a life science machine learning software startup, that aims to improve the speed and effectiveness of selecting biological products for experiments.
READ ARTICLE
Biomedical Researchers to Benefit from New Partnership Between Springer Nature and BenchSci
Springer Nature
Biomedical Researchers to Benefit from New Partnership Between Springer Nature and BenchSci
Springer Nature has partnered with BenchSci, making data from over 200 of the world's top journals available to assist scientists in finding biological products for experiments.
READ ARTICLE
Top 17 Research Tools of 2017
LabWorm
Top 17 Research Tools of 2017
BenchSci made LabWorm's top 17 trending research tools of 2017 that were most appreciated and used by the LabWorm community.
READ ARTICLE
In the Lab of the Future, Robots Run Experiments While Scientists Sleep
Forbes
In the Lab of the Future, Robots Run Experiments While Scientists Sleep
"When it comes to experimental design, companies like BenchSci use artificial intelligence to streamline the process, in this case by finding antibodies to target proteins of interest."
READ ARTICLE
BenchSci’s David Chen: Startup CTOs Need to Be Ready for ‘Unknown Unknowns’
BetaKit
BenchSci’s David Chen: Startup CTOs Need to Be Ready for ‘Unknown Unknowns’
Our CTO, David Chen, was featured in startup news publication BetaKit about using machine learning to help medical researchers solve complex medical challenges.
READ ARTICLE
Game Changer: Benchsci
UHN Research
Game Changer: Benchsci
"BenchSci’s platform will effectively standardize experimental protocols, increase researchers’ productivity, and prevent usage of inappropriate antibodies that lead to erroneous results."
READ ARTICLE
MilliporeSigma Hosts Leading Scientists at Life Science Symposium in Greater Boston
MilliporeSigma
MilliporeSigma Hosts Leading Scientists at Life Science Symposium in Greater Boston
BenchSci CEO and co-founder Liran Belenzon joined world-renowned academic researchers, technology experts, and industry entrepreneurs to speak about advances and opportunities in life science.
READ ARTICLE
ASPET Partners with BenchSci to Increase Discoverability of Its Journals
BenchSci Press Release
ASPET Partners with BenchSci to Increase Discoverability of Its Journals
BenchSci will now include four ASPET journals on its platform to increase discoverability of relevant scientific compounds discussed within ASPET-published articles.
READ ARTICLE
The Great Reproducibility Problem
Labratory News
The Great Reproducibility Problem
"Using filters for specific experimental contexts, BenchSci can help scientists quickly and easily identify the most relevant published figures and associated antibodies within seconds, ensuring that scientists can make an evidence-based decision on antibody selection."
READ ARTICLE
BenchSci Partners with The FASEB Journal to Increase Discoverability of Content
Benchsci Press Release
BenchSci Partners with The FASEB Journal to Increase Discoverability of Content
BenchSci will now include FASEB’s flagship publication, The FASEB Journal (FJ), on its platform to increase discoverability of relevant scientific compounds discussed within The FASEB Journal-published articles.
READ ARTICLE
Science Startups Make Research Faster, Cheaper, More Accurate
Globe and Mail
Science Startups Make Research Faster, Cheaper, More Accurate
"BenchSci has taught a computer to read scientific papers and identify the specific antibodies used as well as other variables, such as specific techniques, tissues and disease used in the experiment."
READ ARTICLE